Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Polatuzumab Vedotin-Piiq in High grade B-cell lymphoma: NCT07184788 Clinical Landscape Report 2026
28 September 2026
NCT07184788 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IMPT-314 in Non-Hodgkin's lymphoma refractory: NCT07188558 Clinical Landscape Report 2026
28 September 2026
NCT07188558 clinical landscape for Non-Hodgkin's lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Doxorubicin Hydrochloride liposomal in Ewing Sarcoma: NCT07194044 Clinical Landscape Report 2026
28 September 2026
NCT07194044 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Triple Negative Breast Cancer: NCT07188246 Clinical Landscape Report 2026
28 September 2026
NCT07188246 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Triple Negative Breast Cancer: NCT07187674 Clinical Landscape Report 2026
28 September 2026
NCT07187674 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: NCT07187869 Clinical Landscape Report 2026
28 September 2026
NCT07187869 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Belzutifan in Renal Cell Carcinoma: NCT07187778 Clinical Landscape Report 2026
28 September 2026
NCT07187778 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanidatamab in Sarcoma: NCT07192068 Clinical Landscape Report 2026
28 September 2026
NCT07192068 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NG2 and DLL3 CAR-T Cells(Shenzhen Geno-Immune Medical Institute) in Melanoma: NCT07193966 Clinical Landscape Report 2026
28 September 2026
NCT07193966 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanzalintinib in Osteosarcoma: NCT07193550 Clinical Landscape Report 2026
28 September 2026
NCT07193550 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lutetium-177 DOTA girentuximab in Metastatic Renal Cell Carcinoma: NCT07197580 Clinical Landscape Report 2026
28 September 2026
NCT07197580 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ST-01156 in Hepatocellular Carcinoma: NCT07197554 Clinical Landscape Report 2026
28 September 2026
NCT07197554 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.